Clearside Biomedical Inc (CLSD) CFO Buys $13,600.00 in Stock

Clearside Biomedical Inc (NASDAQ:CLSD) CFO Charles A. Deignan bought 10,000 shares of Clearside Biomedical stock in a transaction dated Friday, March 15th. The stock was purchased at an average price of $1.36 per share, with a total value of $13,600.00. Following the completion of the purchase, the chief financial officer now owns 76,356 shares in the company, valued at $103,844.16. The purchase was disclosed in a filing with the SEC, which is available at this link.

CLSD stock traded up $0.06 during mid-day trading on Monday, reaching $1.48. 12,204 shares of the company traded hands, compared to its average volume of 1,148,679. The company has a market capitalization of $45.47 million, a P/E ratio of -0.55 and a beta of -1.13. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.59 and a current ratio of 4.59. Clearside Biomedical Inc has a fifty-two week low of $0.99 and a fifty-two week high of $15.33.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.13). The business had revenue of $0.03 million during the quarter. As a group, sell-side analysts forecast that Clearside Biomedical Inc will post -1.26 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in Clearside Biomedical during the 3rd quarter valued at about $216,000. Virtu Financial LLC acquired a new position in Clearside Biomedical during the 4th quarter valued at about $57,000. Dimensional Fund Advisors LP purchased a new position in shares of Clearside Biomedical in the 3rd quarter worth approximately $557,000. Fosun International Ltd purchased a new position in shares of Clearside Biomedical in the 4th quarter worth approximately $178,000. Finally, Northern Trust Corp boosted its stake in shares of Clearside Biomedical by 28.1% in the 2nd quarter. Northern Trust Corp now owns 311,755 shares of the company’s stock worth $3,333,000 after buying an additional 68,357 shares during the last quarter. Institutional investors and hedge funds own 39.93% of the company’s stock.

Several brokerages have recently commented on CLSD. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Thursday, January 3rd. ValuEngine downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Cowen restated a “hold” rating on shares of Clearside Biomedical in a research note on Tuesday, January 22nd. Three analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Clearside Biomedical has an average rating of “Hold” and an average target price of $10.32.

WARNING: “Clearside Biomedical Inc (CLSD) CFO Buys $13,600.00 in Stock” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2019/03/18/clearside-biomedical-inc-clsd-cfo-buys-13600-00-in-stock.html.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Featured Story: What is the Stochastic Momentum Index (SMI)?

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.